Wave Life Sciences (WVE) Operating Income (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Operating Income came in at -$73.8 million in Q2 2026, down 39.89% YoY from -$122.8 million in Q2 2025, and down 135.8% on a QoQ basis from -$31.3 million in Q1 2026.
Wave Life Sciences (WVE) Operating Income (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Operating Income data on file, last reported at -$73.8 million in Q2 2026.
- Quarterly Operating Income fell 39.89% year-over-year to -$73.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$217.9 million (down 51.85% YoY) and the FY2025 annual result came in at -$215.4 million, down 95.09% from the prior year.
- Operating Income slipped to -$73.8 million in Q2 2026, from -$31.3 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $23.0 million in Q4 2024 to a low of -$73.8 million in Q2 2026.
- A 5-year average of -$36.8 million and a median of -$38.5 million in 2022 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 222.94% in 2024, down 1538.23% in 2024.
- Tracing WVE's Operating Income over 5 years: stood at -$43.6 million in 2022, then jumped by 57.11% to -$18.7 million in 2023, then jumped by 222.94% to $23.0 million in 2024, then slumped by 345.86% to -$56.5 million in 2025, then sank by 30.7% to -$73.8 million in 2026.
- The last three Operating Income figures came in at -$73.8 million (Q2 2026), -$31.3 million (Q1 2026), and -$56.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | -73.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -73.80 Mn |
| Mar 31, 2026 | -31.30 Mn |
| Dec 31, 2025 | -56.47 Mn |
| Sep 30, 2025 | -56.35 Mn |
| Jun 30, 2025 | -52.76 Mn |
| Mar 31, 2025 | -49.80 Mn |
| Dec 31, 2024 | 22.97 Mn |
| Sep 30, 2024 | -63.92 Mn |
| Jun 30, 2024 | -35.00 Mn |
| Mar 31, 2024 | -34.46 Mn |
| Dec 31, 2023 | -18.68 Mn |
| Sep 30, 2023 | 4.44 Mn |
| Jun 30, 2023 | -23.47 Mn |
| Mar 31, 2023 | -30.29 Mn |
| Dec 31, 2022 | -43.56 Mn |
| Sep 30, 2022 | -38.90 Mn |
| Jun 30, 2022 | -42.16 Mn |
| Mar 31, 2022 | -38.09 Mn |
| Dec 31, 2021 | -36.11 Mn |
| Sep 30, 2021 | -7.61 Mn |